Suchergebnisse - "Haanen, J"

PubPharm (177)

1

Current strategies of cell and gene therapy for solid tumors : results of the joint international ESMO and CTIWP-EBMT survey

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Comoli, P. | Pentheroudakis, G. | Ruggeri, A. | +14

2

Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study

enthalten in: bioRxiv.org | 2024

von Maat, L. | Van Duin, I. | Verheijden, R. | +23

3

Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes : diagnostic challenges and lessons learned

enthalten in: ESMO open | 2024

von Borgers, J. | van Schijndel, A. | van Thienen, J. | +7

4

Seasonal variation of anti-PD-1 outcome in melanoma-Results from a Dutch patient cohort

enthalten in: Pigment cell & melanoma research | 2024

von Borgers, J. | Burgers, F. | Schina, A. | +18

5

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

enthalten in: Immuno-oncology technology | 2023

von Johanna, I. | Daudeij, A. | Devina, F. | +11

6

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer : Results of the MIMOSA trial

enthalten in: Breast (Edinburgh, Scotland) | 2023

von Geurts, V. | Voorwerk, L. | Balduzzi, S. | +11

7

"One more chance to survive" : the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care

enthalten in: Journal of cancer survivorship : research and practice | 2023

von Egeler, M. | Boomstra, E. | Rohaan, M. | +9

8

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors

enthalten in: ESMO open | 2023

von Oosting, S. | van der Veldt, A. | Fehrmann, R. | +20

9

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Groenland, S. | Janssen, J. | Nijenhuis, C. | +9

10

Extended follow-up from JAVELIN Renal 101 : subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

enthalten in: ESMO open | 2023

von Haanen, J. | Larkin, J. | Choueiri, T. | +10

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]